Omega interferon is produced by BioMedicines. Phase II clinical testing has been completed
in patients with hepatitis C at the Scripps Clinic as well as in multiple centers in Europe, and
followup is underway. The company is trying to develop a new form of omega interferon that will
target only the liver so that it will be more effective and have fewer side effects than present therapies (
BioMedicines has acquired rights to a delivery system that may permit the administration of omega interferon for weeks or months with a single administration in the form of an implant. (DUROS® is a registered trademark of ALZA Corporation.) This is in Preclinical trials.